Atlas Trials

Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years

Clinical trial NCT01423084 · COMPLETED

Trial details

NCT number
NCT01423084
Sponsor
Novartis
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Meningococcal DiseaseMeningococcal Meningitis
Start date
2011-08-01
Primary completion
2011-12-01
Enrollment
344

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.